RUBCN Cancer Research Results

RUBCN, Rubicon Autophagy Regulator: Click to Expand ⟱
Source:
Type:

RUBCN - Rubicon Autophagy Regulator

Abbreviation: RUBCN, Rubicon

Alternative Names: RUN Domain Beclin-1-Interacting and Cysteine-Rich Domain-Containing Protein

Type: Autophagy regulator / Beclin 1-VPS34 complex regulator / noncanonical autophagy protein

Function: Rubicon is a negative regulator of canonical autophagy that inhibits autophagosome maturation and autophagosome-lysosome fusion through interactions with the Beclin 1-VPS34-UVRAG machinery and related fusion components. In contrast, Rubicon is required for LC3-associated phagocytosis (LAP) and other noncanonical ATG8/LC3 conjugation pathways.

Cancer: ↑ Rubicon expression is increased in several cancers and can promote tumor progression by suppressing canonical autophagic flux and by supporting Rubicon-dependent noncanonical pathways such as LAP that may reduce antitumor immune activity. High RUBCN expression has been associated with poor prognosis in some tumor types.

Favorable Direction in Cancer:RUBCN may be favorable in cancers where Rubicon promotes tumor progression or immunosuppressive LAP. However, effects can depend on tumor type, immune context, and Rubicon isoform.

Interpretation Note: Rubicon has opposite functional roles in different autophagy pathways: it inhibits canonical autophagy but is required for LC3-associated phagocytosis. Therefore, RUBCN ↑ should not automatically be interpreted simply as autophagy ↓ without identifying which pathway is being measured.



Scientific Papers found: Click to Expand⟱
8235- LCA,    Anticancer effects of licochalcones: A review of the mechanisms
- Review, Var, NA
mt-Apoptosis↑, TumAuto↑, TumCMig↓, LC3‑Ⅱ/LC3‑Ⅰ↑, ATG5↑, ATG7↑, p62↑, CHOP/DDIT3↑, ER Stress↑, UPR↑, ATG3↑, Beclin-1/ATG6↑, ATG16L1↑, PERK↑, ATF4↑, ATP↓, Hif1a↓, GLUT1↓, PDK1 / PDPK1↓, Bcl-xL↓, Bcl-2↓, BAD↑, BAX↑, Casp3↑, survivin↓, EGFR↓, ERK↓, Akt↓, mtDam↑, MMP↓, Cyt‑c↑, Casp↑, MDM2↓, CycB/CCNB1↓, CDC2↓, CDC25↓, TumCCA↑, TumCP↓, Wnt↓, β-catenin/ZEB1↓, Sp1/3/4↓, MMP-10↓, MMP3↓, TumCI↓, Imm↑, PD-L1↓, ROS↑, 4E-BP1↓, eIF2α↓, PI3K↓, mTOR↓, p‑cMET↑, Ca+2↑, RUBCN↓, ATG13↑, TSC1↑, TSC2↑, PRAS40↑, PP2A↑, ULK1/ATG1↑, THEM4/CTMP↑, DR5↑, Fas↑, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, PKCδ↓, P70S6K↓, VEGF↓, angioG↓, HK2↓, Glycolysis↓, TrxR1↓, APAF1↑, cl‑PARP↑, Bax:Bcl2↑, ABCG2↓, BioEnh↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0)

ATG13↑, 1,   ATG16L1↑, 1,   RUBCN↓, 1,   THEM4/CTMP↑, 1,   TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, 1,   ULK1/ATG1↑, 1,  

Redox & Oxidative Stress(tgid=1)

ROS↑, 1,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3)

ATP↓, 1,   CDC2↓, 1,   CDC25↓, 1,   MMP↓, 1,   mtDam↑, 1,  

Core Metabolism/Glycolysis(tgid=4)

ATG7↑, 1,   Glycolysis↓, 1,   HK2↓, 1,   PDK1 / PDPK1↓, 1,  

Cell Death(tgid=5)

Akt↓, 1,   APAF1↑, 1,   mt-Apoptosis↑, 1,   BAD↑, 1,   BAX↑, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   Casp↑, 1,   Casp3↑, 1,   Cyt‑c↑, 1,   DR5↑, 1,   Fas↑, 1,   MDM2↓, 1,   survivin↓, 1,  

Kinase & Signal Transduction(tgid=6)

Sp1/3/4↓, 1,   TSC2↑, 1,  

Protein Folding & ER Stress(tgid=8)

CHOP/DDIT3↑, 1,   eIF2α↓, 1,   ER Stress↑, 1,   PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9)

ATG3↑, 1,   ATG5↑, 1,   Beclin-1/ATG6↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   p62↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10)

cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11)

CycB/CCNB1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12)

4E-BP1↓, 1,   p‑cMET↑, 1,   ERK↓, 1,   mTOR↓, 1,   P70S6K↓, 1,   PI3K↓, 1,   Wnt↓, 1,  

Migration(tgid=13)

Ca+2↑, 1,   MMP-10↓, 1,   MMP3↓, 1,   PKCδ↓, 1,   TSC1↑, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14)

angioG↓, 1,   ATF4↑, 1,   EGFR↓, 1,   Hif1a↓, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15)

GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16)

Imm↑, 1,   PD-L1↓, 1,  

Protein Aggregation(tgid=19)

PP2A↑, 1,  

Drug Metabolism & Resistance(tgid=21)

ABCG2↓, 1,   BioEnh↑, 1,  

Clinical Biomarkers(tgid=22)

EGFR↓, 1,   PD-L1↓, 1,  

Functional Outcomes(tgid=23)

PRAS40↑, 1,  
Total Targets: 78

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: RUBCN, Rubicon Autophagy Regulator
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1786  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page